TY - JOUR
T1 - Autograft cellular composition and outcome in NHL patients
T2 - results of the prospective multicenter GOA study
AU - Turunen, Antti
AU - Valtola, Jaakko
AU - Partanen, Anu
AU - Ropponen, Antti
AU - Kuittinen, Outi
AU - Kuitunen, Hanne
AU - Vasala, Kaija
AU - Ågren, Lasse
AU - Penttilä, Karri
AU - Keskinen, Leena
AU - Savolainen, Eeva Riitta
AU - Pyörälä, Marja
AU - Kuittinen, Taru
AU - Selander, Tuomas
AU - Mäntymaa, Pentti
AU - Pelkonen, Jukka
AU - Jantunen, Esa
AU - Varmavuo, Ville
N1 - Funding Information:
The GOA study was financially supported by grants from North Savo Hospital District EVO and VTR Funds. The GOA study received also a study grant from Sanofi. Dr. Turunen is grateful for the grants provided by North Savo Hospital District Research Fund, The Finnish Blood Disease Research Foundation, and The Finnish Medical Foundation.
Publisher Copyright:
© 2020 Informa UK Limited, trading as Taylor & Francis Group.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020
Y1 - 2020
N2 - Autologous stem cell transplantation (auto-SCT) is an established treatment option in patients with non-Hodgkin lymphoma (NHL). In this prospective multicenter study, the effect of infused blood graft cellular composition on post-transplant outcome was analyzed in 129 NHL patients. Higher graft CD34+ cell content (>2.5 × 106/kg) correlated with better progression-free survival (PFS) (p=.009) and overall survival (OS) (p=.004). Higher graft CD34+CD133+CD38– counts (>0.08 × 106/kg) were also linked with better PFS (p=.03) and OS (p=.004), and these survival benefits retained in multivariate analyses. Higher infused CD3+CD4+ cell count (>37 × 106/kg) predicted better PFS (p=.013) and OS (p=.007) in multivariate analysis. Autograft cellular composition seems to impact outcome in NHL patients. These observations regarding composition of optimal graft in autologous setting should be validated in an independent patient series or in a randomized study.
AB - Autologous stem cell transplantation (auto-SCT) is an established treatment option in patients with non-Hodgkin lymphoma (NHL). In this prospective multicenter study, the effect of infused blood graft cellular composition on post-transplant outcome was analyzed in 129 NHL patients. Higher graft CD34+ cell content (>2.5 × 106/kg) correlated with better progression-free survival (PFS) (p=.009) and overall survival (OS) (p=.004). Higher graft CD34+CD133+CD38– counts (>0.08 × 106/kg) were also linked with better PFS (p=.03) and OS (p=.004), and these survival benefits retained in multivariate analyses. Higher infused CD3+CD4+ cell count (>37 × 106/kg) predicted better PFS (p=.013) and OS (p=.007) in multivariate analysis. Autograft cellular composition seems to impact outcome in NHL patients. These observations regarding composition of optimal graft in autologous setting should be validated in an independent patient series or in a randomized study.
KW - autologous stem cell transplantation
KW - flow cytometry
KW - graft cellular composition
KW - Non-Hodgkin lymphoma
KW - outcome
U2 - 10.1080/10428194.2020.1762879
DO - 10.1080/10428194.2020.1762879
M3 - Article
C2 - 32419549
AN - SCOPUS:85085469981
SN - 1042-8194
VL - 61
SP - 2082
EP - 2092
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 9
ER -
